drugset / Trial / NCT05583357

Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351

NCT05583357

Phase 0 Unknown 40 enrolled Livzon Pharmaceutical Group Inc.
RandomizedCrossoverOpen-labelPrevention

Summary

It is a single center, randomized, open-labeled, blind endpoint evaluation, exploratory clinical study to evaluate the safety and immunogenicity of bivalent vaccine V-01D-351 as a booster.

Timeline

Start
2022-08-15
Primary completion
2022-09-13
Completion
2023-08-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator CoronaVac Vaccine
Subject V-01D-351 Vaccine

Indications